Found: 13
Select item for more details and to access through your institution.
733. Pharmacokinetic–Pharmacodynamic (PK–PD) Analyses for Alanine Aminotransferase (ALT) Using Phase 3 Data From Omadacycline (OMC)-Treated Patients.
- Published in:
- Open Forum Infectious Diseases, 2019, v. 6, p. S328, doi. 10.1093/ofid/ofz360.801
- By:
- Publication type:
- Article
734. Modeling the Pharmacokinetics and Pharmacodynamics of Intravenous and Oral Omadacycline with and without a Loading Dose.
- Published in:
- Open Forum Infectious Diseases, 2019, v. 6, p. S329, doi. 10.1093/ofid/ofz360.802
- By:
- Publication type:
- Article
1561. Omadacycline Pharmacokinetics: Influence of Mortality Risk Score Among Patients with Community-Acquired Bacterial Pneumonia.
- Published in:
- Open Forum Infectious Diseases, 2019, v. 6, p. S569, doi. 10.1093/ofid/ofz360.1425
- By:
- Publication type:
- Article
Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials.
- Published in:
- 2017
- By:
- Publication type:
- journal article
The Novel Aminomethylcycline Omadacycline Has High Specificity for the Primary Tetracycline-Binding Site on the Bacterial Ribosome.
- Published in:
- Antibiotics (2079-6382), 2016, v. 5, n. 4, p. 32, doi. 10.3390/antibiotics5040032
- By:
- Publication type:
- Article
New Antimicrobial Agents . . . but No Susceptibility Tests!
- Published in:
- 2016
- By:
- Publication type:
- Letter to the Editor
Outcomes of high-dose levofloxacin therapy remain bound to the levofloxacin minimum inhibitory concentration in complicated urinary tract infections.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Outcomes with daptomycin in the treatment of Staphylococcus aureus infections with a range of vancomycin MICs.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2010, v. 65, n. 8, p. 1784, doi. 10.1093/jac/dkq200
- By:
- Publication type:
- Article
Effects of daptomycin in combination with other antimicrobial agents: a review of in vitro and animal model studies.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2009, v. 64, n. 6, p. 1130, doi. 10.1093/jac/dkp346
- By:
- Publication type:
- Article
Daptomycin tested against 915 bloodstream isolates of viridans group streptococci (eight species) and Streptococcus bovis.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2005, v. 55, n. 4, p. 574, doi. 10.1093/jac/dki032
- By:
- Publication type:
- Article
Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2005, v. 55, n. 3, p. 283, doi. 10.1093/jac/dkh546
- By:
- Publication type:
- Article
Cryptococcus neoformans var. gattii can exploit Acanthamoeba castellanii for growth.
- Published in:
- Medical Mycology, 2004, v. 42, n. 2, p. 149, doi. 10.1080/13693786310001616500
- By:
- Publication type:
- Article